Navigation Links
Isis Reports Strong Financial Results and Highlights for Fiscal Year 2008
Date:2/25/2009

e Call

At 08:30 a.m. Eastern Time today, February 25, Isis will conduct a live webcast conference call to discuss this earnings release and related activities. Interested parties may access the webcast at www.isispharm.com, or listen to the call by dialing 877-852-6543. A webcast replay will be available for a limited time at the same address.

About Isis Pharmaceuticals, Inc.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis is a joint owner of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott Molecular Inc. are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.

This press release includes forward-looking statements regarding Isis Pharmaceuticals' business, the financial position and outlook for Isis as well as Regulus its majority-owned subsidiary, and the therapeutic and commercial potential of the Company's technologies and products in development. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement,
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. Lehigh Valley-Based PPO, Valley Preferred, Reports Marked Improvement in Disease Management & Wellness Outcomes
2. Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
3. Symmetry Medical Reports Fourth Quarter and Full Year 2008 Financial Results
4. ev3 Inc. Reports 2008 Fourth Quarter and Full-Year Financial Results and 2009 Guidance
5. Update: Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results
6. HealthSouth Reports Results for Fourth Quarter Ended December 31, 2008
7. Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results
8. Solta Medical Reports Fourth Quarter and Full Year 2008 Results
9. 1 in 10 Ex-NFL Players Used Steroids, Poll Reports
10. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
11. Nyer Medical Group, Inc. Reports Revenues of $19.0 Million for the Quarter Ended December 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Newark, NJ (PRWEB) July 24, 2014 ... which will give one lucky family a rent-free week ... only until August 3, 2014. Don’t miss your chance ... The sweepstakes is open to all New Jersey residents, ... Horizon BCBSNJ Facebook page, http://www.facebook.com/HorizonBCBSNJ . , ...
(Date:7/24/2014)... with high-throughput data generated by breast cancer biologists ... computational method to determine how gene networks are ... as they respond to potential cancer therapy agents., ... each other in laboratory-grown cells is described in ... PLOS Computational Biology . , The method ...
(Date:7/24/2014)... Human Papillomavirus Vaccination (HPV) even after becoming sexually ... results than those who were never vaccinated. These ... Diseases . , Researchers from Boston University ... conducted a cross-sectional study of 235 women age ... HPV status and demographic and behavioral characteristics were ...
(Date:7/24/2014)... Los Angeles, CA (PRWEB) July 24, 2014 ... (FDA), American Optometric Association (AOA) and the Entertainment ... artists from the TV series American Horror Story ... to bring the dramatic realities of illegal ... public service campaign, which has already reached tens-of-thousands, ...
(Date:7/24/2014)... 4th Annual National Venous Interventional Summit is available ... an established Venous Endovascular Interventional Strategies group comprised ... is to provide a "How To" meeting for ... in advancing their knowledge and skills in venous ... own comprehensive venous interventional program. Topics at this ...
Breaking Medicine News(10 mins):Health News:(Beach) Sands of Time Running out to Enter Horizon Blue Cross Blue Shield of New Jersey’s 2014 “Back to the Boardwalk” Sweepstakes 2Health News:Gene changes in breast cancer cells pinpointed with new computational method 2Health News:Gene changes in breast cancer cells pinpointed with new computational method 3Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 2Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 3Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 4Health News:Preliminary agenda available for 4th VEINS Conference to be held October 9-12 in Chicago 2
... announced today that,the physicians of Great Lakes Radiologists, one of ... Aurora Medical Group. , ... and,clinics. , "These are ... care we provide for Aurora patients," said Jeff Bailet, M.D., ...
... and Management Realigned to Provide Full Support for Clinical ... Md., Dec. 15 EntreMed, Inc. (Nasdaq: ... to focus the Company,s resources on its most promising ... part of the Company,s overall plan to lower operating ...
... 15, 2008 Researchers from Yale University School ... magnification to standard white light colonoscopy in differentiating ... NBI was not more accurate than white light ... curve for these experienced endoscopists using NBI as ...
... brakes on killer disease, scientists say , , MONDAY, Dec. ... gene may provide a new target for treating deadly ... Mayo Clinic College of Medicine in Minnesota show the ... in another gene that, in a mutated form, has ...
... Imaging(R),Inc., a wholly owned subsidiary of Mercury Computer ... it has received FDA 510(k) clearance to market,its ... This release brings,significant enhancements to its prior offerings ... Neuroradiology and Oncology applications. The Neuro,option facilitates brain ...
... 15 Millennium Biotechnologies Group, Inc. (OTC Bulletin Board: ... in the Clinical and Sports Nutrition Market, announces financial results ... , Net revenue for the third ... in the third quarter 2007. The Company reduced its, ...
Cached Medicine News:Health News:Great Lakes Radiologists to Join Aurora Medical Group 2Health News:EntreMed Focuses on Development of ENMD-2076 2Health News:EntreMed Focuses on Development of ENMD-2076 3Health News:EntreMed Focuses on Development of ENMD-2076 4Health News:EntreMed Focuses on Development of ENMD-2076 5Health News:Narrow-band imaging comparable to white light colonoscopy in differentiating colorectal polyps 2Health News:Narrow-band imaging comparable to white light colonoscopy in differentiating colorectal polyps 3Health News:Narrow-band imaging comparable to white light colonoscopy in differentiating colorectal polyps 4Health News:Pancreatic Cancer May Have a New Foe 2Health News:Visage Imaging Receives FDA 510(k) Clearance for its Latest Thin Client Product Release 2Health News:Visage Imaging Receives FDA 510(k) Clearance for its Latest Thin Client Product Release 3Health News:Visage Imaging Receives FDA 510(k) Clearance for its Latest Thin Client Product Release 4Health News:Millennium Biotechnologies Reports Strong Third Quarter Revenue and Financial Results 2Health News:Millennium Biotechnologies Reports Strong Third Quarter Revenue and Financial Results 3
(Date:7/24/2014)... July 24, 2014 Consolidated Net Profit increased ... Highlights   , India Business grew by 20.87% ... to Rs. 4,886.70 Mn Rest of World (ROW) Business ... Business grew by 34.53% to Rs. 977.26 Mn Latin ... Glenmark Pharmaceuticals Limited, the research-led global integrated pharmaceutical ...
(Date:7/24/2014)... , July 24, 2014 /PRNewswire-iReach/ -- Delivery ... once order is placed. Photo - ... a professional and in-depth market survey on Global ... reviews the basic information of Hemodialysis Machine including ... then explores global and China,s top manufacturers of ...
(Date:7/24/2014)... Scotland , July 24, 2014 Cancer patients ... gain access to state-of-the-art cancer treatment closer to home when ... next year. Varian Medical Systems (NYSE: VAR ... an order was placed in June for four TrueBeam™ medical ... systems, which offer fast and efficient radiotherapy and radiosurgery treatments, ...
Breaking Medicine Technology:Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 2Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 3Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 5Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 2Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 3
... Incorporated (Nasdaq: ARAY ), the premier radiation oncology ... Euan S. Thomson, Ph.D., is scheduled to present at the ... City on Tuesday November 15, 2011 at 10:30 a.m. EST/7:30 ... the Stephens Fall Investment Conference in New York City on ...
... PARSIPPANY, N.J., Nov. 10, 2011 Columbia Laboratories, Inc. ... (NYSE: WPI ), today confirmed that the ... Food and Drug Administration (FDA) is scheduled to review ... for the reduction of risk of preterm birth in ...
Cached Medicine Technology:Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA 2Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA 3Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA 4
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
... glucose monitor elevates bedside glucose testing to ... approaches the quality of central laboratory testing. ... measuring strip technology. Current glucose strips ... Multi-Well system measures and corrects hematocrit interference ...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
... The BreatheX is a wearable CPAP ... treatment of sleep apnea. The lightweight BreatheX ... of therapy with its built-in, rechargeable battery, ... users will no longer need to be ...
Medicine Products: